COZpD Clinical Trial

Since it is still in Clinical Trial status you would have to be accepted nto the program based on the criteria out-lined, but I'm like you.....I'd go for it!
Just read several article from NIH and explored Medical centers finding out that in fact that lung transplants can and are being done robotically , NYC Langone, Duke....discouraging when one the initial run through there was nothing except the "crack you chest" method....so what changed in 6- months? Centers have even upped the age of candidates that they would consider under certain circumstances from 65- 75. So why is this info not readily available for those of us that are researching it?

Yes, I've been researching it. Here is what I've found so far:

Autologous P63+ lung progenitor cell therapy involves a meticulous process of selecting COPD patients, isolating and culturing their P63+ cells, transplanting them back into the lungs, and monitoring outcomes over 24 weeks. The therapy shows promise in improving lung function and quality of life, particularly for patients with mild emphysema, but remains experimental.

Overview of Autologous P63+ Lung Progenitor Cell Therapy

This therapy leverages P63+ progenitor cells, a type of stem cell found in the airway basal layer of the lungs, known for their ability to regenerate airway and alveolar (air sac) tissues. The approach is autologous, meaning it uses the patient’s own cells, reducing the risk of rejection. The therapy is in early clinical trials, primarily led by Professor Wei Zuo at Tongji University in Shanghai and Regend Therapeutics Ltd. in China. Early results suggest it is safe and may improve lung function.

The following outlines the detailed process of autologous P63+ lung progenitor cell therapy for COPD, based on clinical trial data and scientific reports:

1. Participant Selection
• Purpose: Identify suitable candidates with COPD who may benefit from the therapy.
• Criteria: Patients with stage II to IV COPD (moderate to very severe) are selected, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. These patients typically have a diffusing capacity of the lungs for carbon monoxide (DLCO) less than 80% of the predicted value, indicating impaired gas exchange.
• Process:
o Patients undergo medical screening, including lung function tests (spirometry, DLCO), imaging (CT scans), and clinical assessments to confirm COPD severity and rule out contraindications (e.g., active infections or severe comorbidities).
o In clinical trials, participants are divided into an intervention group (receiving cell therapy) and a control group (receiving standard care or placebo). For example, a phase I trial included 28 participants, with 20 evaluable at the end (17 intervention, 3 control) (PubMed).
• Considerations: Patients with severe COPD (35% severe, 53% extremely severe in trials) are prioritized, as they have significant lung damage but are still stable enough for experimental treatment.

2. Cell Isolation
• Purpose: Collect P63+ progenitor cells from the patient’s lungs for culturing.
• Procedure:
o A bronchoscopy is performed under local anesthesia or mild sedation. A bronchoscope, a flexible tube with a camera, is inserted through the mouth or nose into the airways.
o The bronchoscope is used to gently brush the airway basal layer, collecting P63+ progenitor cells. This process, known as bronchoscopic brushing, is minimally invasive but may cause mild discomfort or coughing.
o The collected cells are immediately transported to a laboratory under sterile conditions to ensure viability.
• Details: P63+ progenitor cells are specifically targeted because they express the P63 protein, which is critical for their regenerative potential. These cells can differentiate into various epithelial cell types that line the airways and alveoli (MedPage Today).
• Safety: Bronchoscopy is a standard procedure but carries minor risks, such as bleeding or infection, which are monitored during and after the procedure.

3. Cell Culture
• Purpose: Expand the number of P63+ progenitor cells to create a sufficient quantity for transplantation.
• Procedure:
o The isolated cells are cultured in a specialized laboratory for 3 to 5 weeks. This involves placing the cells in a controlled environment with nutrients and growth factors to promote proliferation.
o The cells are cloned to produce up to 1,000 million cells, ensuring enough for effective treatment (ERS News).
o Quality control tests are conducted to verify the cells’ purity, viability, and P63 expression, ensuring they retain their regenerative properties.
• Details: The culturing process is critical, as it determines the therapy’s potential efficacy. Higher P63 expression is associated with better treatment outcomes, as shown in transcriptomic analysis (PubMed).
• Considerations: The 3- to 5-week duration balances the need for sufficient cell numbers with the risk of cellular changes during prolonged culturing.

4. Cell Transplantation
• Purpose: Deliver the cultured P63+ progenitor cells back into the patient’s lungs to initiate tissue repair.
• Procedure:
o A second bronchoscopy is performed to transplant the cultured cells into the lungs. The cells are suspended in a sterile solution and delivered directly into the airways and alveoli.
o The dosage ranges from 0.7 × 10^6 to 5.2 × 10^6 cells per kilogram of body weight, tailored to the patient’s size and condition (PubMed).
o The procedure is performed under similar conditions as the initial bronchoscopy, with local anesthesia or sedation.
• Details: The cells are expected to integrate into the damaged lung tissue, regenerating the epithelial lining of the airways and alveoli. This process aims to improve gas exchange and lung function (Inside Precision Medicine).
• Safety: The transplantation is well-tolerated, with no significant side effects reported in trials, though minor bronchoscopy-related adverse events (e.g., sore throat) may occur.

5. Follow-up Period
• Purpose: Monitor patients for safety and efficacy over an extended period.
• Procedure:
o Patients are followed for 24 weeks (6 months) post-transplantation, with regular check-ups to assess lung function, exercise capacity, quality of life, and adverse events.
o Key metrics include:
 DLCO: Measures gas exchange efficiency. In trials, treated patients’ median DLCO increased from 30% to 39.7% at 12 weeks and 40.3% at 24 weeks (Hospital Healthcare Europe).
 Six-Minute Walk Distance (6MWD): Assesses exercise capacity. Treated patients showed a median increase from 410 meters to 447 meters at 24 weeks.
 St. George’s Respiratory Questionnaire (SGRQ): Evaluates quality of life. Scores decreased from 51.3% to 44.2%, indicating improvement.
 Imaging: CT scans monitor structural changes. Two patients with mild emphysema showed resolution of lesions at 24 weeks.

Safety is assessed by tracking adverse events, graded on severity (1 to 5, with 3 to 5 being serious). No grade 3 to 5 adverse events or serious adverse events were reported (PubMed).
• Details: The follow-up period is critical to determine the therapy’s long-term safety and efficacy. Transcriptomic analysis showed that higher P63 expression correlated with better outcomes, guiding future refinements.

I would much rather do stem cell than transplant. Just exchanging one problem for a lot of others, like diabetes, kidney failure, rejection and numerous tests and medication. I know stem cell is not a cure but even if it helped a little it would be worth it to me.

Here are the contact details, also some other research that is happening around the world.

Professor Wei Zuo and Team (Tongji University and Regend Therapeutics Ltd.)
• Institution: Tongji University, Shanghai, China and Regend Therapeutics Ltd.
• Research Focus: Autologous P63+ lung progenitor cell therapy to regenerate damaged lung tissue in COPD patients.

Other research:

• Stem Cell Research: Various groups are exploring stem cells, which can differentiate into any cell type, for lung repair. However, results have been inconsistent compared to progenitor cells, which are more specific to lung tissue (Labiotech.eu).

• Hyaluronan Therapy: A pilot study led by Drs. Stavros Garantziotis (NIH) and Raffaele Incalzi (Campus Bio-Medico University, Italy) found that inhaled hyaluronan, a naturally occurring sugar, improved lung function in hospitalized COPD patients by reducing inflammation and aiding tissue repair (NIH News).

• Precision Medicine: Researchers are investigating COPD subtypes based on inflammatory profiles to develop targeted therapies. This work is still in early stages but could lead to personalized treatments (Time Magazine).

Institutions and Organizations
• National Heart, Lung, and Blood Institute (NHLBI): Supports COPD research and developed the COPD National Action Plan to improve diagnosis, prevention, and treatment (NHLBI).
• Royal Brompton & Harefield Hospitals (UK): Conducting trials on novel treatments, such as vagus nerve ablation to reduce airway obstruction (RBHT).

Yes, I've been researching it. Here is what I've found so far:

Autologous P63+ lung progenitor cell therapy involves a meticulous process of selecting COPD patients, isolating and culturing their P63+ cells, transplanting them back into the lungs, and monitoring outcomes over 24 weeks. The therapy shows promise in improving lung function and quality of life, particularly for patients with mild emphysema, but remains experimental.

Overview of Autologous P63+ Lung Progenitor Cell Therapy

This therapy leverages P63+ progenitor cells, a type of stem cell found in the airway basal layer of the lungs, known for their ability to regenerate airway and alveolar (air sac) tissues. The approach is autologous, meaning it uses the patient’s own cells, reducing the risk of rejection. The therapy is in early clinical trials, primarily led by Professor Wei Zuo at Tongji University in Shanghai and Regend Therapeutics Ltd. in China. Early results suggest it is safe and may improve lung function.

The following outlines the detailed process of autologous P63+ lung progenitor cell therapy for COPD, based on clinical trial data and scientific reports:

1. Participant Selection
• Purpose: Identify suitable candidates with COPD who may benefit from the therapy.
• Criteria: Patients with stage II to IV COPD (moderate to very severe) are selected, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. These patients typically have a diffusing capacity of the lungs for carbon monoxide (DLCO) less than 80% of the predicted value, indicating impaired gas exchange.
• Process:
o Patients undergo medical screening, including lung function tests (spirometry, DLCO), imaging (CT scans), and clinical assessments to confirm COPD severity and rule out contraindications (e.g., active infections or severe comorbidities).
o In clinical trials, participants are divided into an intervention group (receiving cell therapy) and a control group (receiving standard care or placebo). For example, a phase I trial included 28 participants, with 20 evaluable at the end (17 intervention, 3 control) (PubMed).
• Considerations: Patients with severe COPD (35% severe, 53% extremely severe in trials) are prioritized, as they have significant lung damage but are still stable enough for experimental treatment.

2. Cell Isolation
• Purpose: Collect P63+ progenitor cells from the patient’s lungs for culturing.
• Procedure:
o A bronchoscopy is performed under local anesthesia or mild sedation. A bronchoscope, a flexible tube with a camera, is inserted through the mouth or nose into the airways.
o The bronchoscope is used to gently brush the airway basal layer, collecting P63+ progenitor cells. This process, known as bronchoscopic brushing, is minimally invasive but may cause mild discomfort or coughing.
o The collected cells are immediately transported to a laboratory under sterile conditions to ensure viability.
• Details: P63+ progenitor cells are specifically targeted because they express the P63 protein, which is critical for their regenerative potential. These cells can differentiate into various epithelial cell types that line the airways and alveoli (MedPage Today).
• Safety: Bronchoscopy is a standard procedure but carries minor risks, such as bleeding or infection, which are monitored during and after the procedure.

3. Cell Culture
• Purpose: Expand the number of P63+ progenitor cells to create a sufficient quantity for transplantation.
• Procedure:
o The isolated cells are cultured in a specialized laboratory for 3 to 5 weeks. This involves placing the cells in a controlled environment with nutrients and growth factors to promote proliferation.
o The cells are cloned to produce up to 1,000 million cells, ensuring enough for effective treatment (ERS News).
o Quality control tests are conducted to verify the cells’ purity, viability, and P63 expression, ensuring they retain their regenerative properties.
• Details: The culturing process is critical, as it determines the therapy’s potential efficacy. Higher P63 expression is associated with better treatment outcomes, as shown in transcriptomic analysis (PubMed).
• Considerations: The 3- to 5-week duration balances the need for sufficient cell numbers with the risk of cellular changes during prolonged culturing.

4. Cell Transplantation
• Purpose: Deliver the cultured P63+ progenitor cells back into the patient’s lungs to initiate tissue repair.
• Procedure:
o A second bronchoscopy is performed to transplant the cultured cells into the lungs. The cells are suspended in a sterile solution and delivered directly into the airways and alveoli.
o The dosage ranges from 0.7 × 10^6 to 5.2 × 10^6 cells per kilogram of body weight, tailored to the patient’s size and condition (PubMed).
o The procedure is performed under similar conditions as the initial bronchoscopy, with local anesthesia or sedation.
• Details: The cells are expected to integrate into the damaged lung tissue, regenerating the epithelial lining of the airways and alveoli. This process aims to improve gas exchange and lung function (Inside Precision Medicine).
• Safety: The transplantation is well-tolerated, with no significant side effects reported in trials, though minor bronchoscopy-related adverse events (e.g., sore throat) may occur.

5. Follow-up Period
• Purpose: Monitor patients for safety and efficacy over an extended period.
• Procedure:
o Patients are followed for 24 weeks (6 months) post-transplantation, with regular check-ups to assess lung function, exercise capacity, quality of life, and adverse events.
o Key metrics include:
 DLCO: Measures gas exchange efficiency. In trials, treated patients’ median DLCO increased from 30% to 39.7% at 12 weeks and 40.3% at 24 weeks (Hospital Healthcare Europe).
 Six-Minute Walk Distance (6MWD): Assesses exercise capacity. Treated patients showed a median increase from 410 meters to 447 meters at 24 weeks.
 St. George’s Respiratory Questionnaire (SGRQ): Evaluates quality of life. Scores decreased from 51.3% to 44.2%, indicating improvement.
 Imaging: CT scans monitor structural changes. Two patients with mild emphysema showed resolution of lesions at 24 weeks.

Safety is assessed by tracking adverse events, graded on severity (1 to 5, with 3 to 5 being serious). No grade 3 to 5 adverse events or serious adverse events were reported (PubMed).
• Details: The follow-up period is critical to determine the therapy’s long-term safety and efficacy. Transcriptomic analysis showed that higher P63 expression correlated with better outcomes, guiding future refinements.

Yes, I've been researching it. Here is what I've found so far:

Autologous P63+ lung progenitor cell therapy involves a meticulous process of selecting COPD patients, isolating and culturing their P63+ cells, transplanting them back into the lungs, and monitoring outcomes over 24 weeks. The therapy shows promise in improving lung function and quality of life, particularly for patients with mild emphysema, but remains experimental.

Overview of Autologous P63+ Lung Progenitor Cell Therapy

This therapy leverages P63+ progenitor cells, a type of stem cell found in the airway basal layer of the lungs, known for their ability to regenerate airway and alveolar (air sac) tissues. The approach is autologous, meaning it uses the patient’s own cells, reducing the risk of rejection. The therapy is in early clinical trials, primarily led by Professor Wei Zuo at Tongji University in Shanghai and Regend Therapeutics Ltd. in China. Early results suggest it is safe and may improve lung function.

The following outlines the detailed process of autologous P63+ lung progenitor cell therapy for COPD, based on clinical trial data and scientific reports:

1. Participant Selection
• Purpose: Identify suitable candidates with COPD who may benefit from the therapy.
• Criteria: Patients with stage II to IV COPD (moderate to very severe) are selected, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. These patients typically have a diffusing capacity of the lungs for carbon monoxide (DLCO) less than 80% of the predicted value, indicating impaired gas exchange.
• Process:
o Patients undergo medical screening, including lung function tests (spirometry, DLCO), imaging (CT scans), and clinical assessments to confirm COPD severity and rule out contraindications (e.g., active infections or severe comorbidities).
o In clinical trials, participants are divided into an intervention group (receiving cell therapy) and a control group (receiving standard care or placebo). For example, a phase I trial included 28 participants, with 20 evaluable at the end (17 intervention, 3 control) (PubMed).
• Considerations: Patients with severe COPD (35% severe, 53% extremely severe in trials) are prioritized, as they have significant lung damage but are still stable enough for experimental treatment.

2. Cell Isolation
• Purpose: Collect P63+ progenitor cells from the patient’s lungs for culturing.
• Procedure:
o A bronchoscopy is performed under local anesthesia or mild sedation. A bronchoscope, a flexible tube with a camera, is inserted through the mouth or nose into the airways.
o The bronchoscope is used to gently brush the airway basal layer, collecting P63+ progenitor cells. This process, known as bronchoscopic brushing, is minimally invasive but may cause mild discomfort or coughing.
o The collected cells are immediately transported to a laboratory under sterile conditions to ensure viability.
• Details: P63+ progenitor cells are specifically targeted because they express the P63 protein, which is critical for their regenerative potential. These cells can differentiate into various epithelial cell types that line the airways and alveoli (MedPage Today).
• Safety: Bronchoscopy is a standard procedure but carries minor risks, such as bleeding or infection, which are monitored during and after the procedure.

3. Cell Culture
• Purpose: Expand the number of P63+ progenitor cells to create a sufficient quantity for transplantation.
• Procedure:
o The isolated cells are cultured in a specialized laboratory for 3 to 5 weeks. This involves placing the cells in a controlled environment with nutrients and growth factors to promote proliferation.
o The cells are cloned to produce up to 1,000 million cells, ensuring enough for effective treatment (ERS News).
o Quality control tests are conducted to verify the cells’ purity, viability, and P63 expression, ensuring they retain their regenerative properties.
• Details: The culturing process is critical, as it determines the therapy’s potential efficacy. Higher P63 expression is associated with better treatment outcomes, as shown in transcriptomic analysis (PubMed).
• Considerations: The 3- to 5-week duration balances the need for sufficient cell numbers with the risk of cellular changes during prolonged culturing.

4. Cell Transplantation
• Purpose: Deliver the cultured P63+ progenitor cells back into the patient’s lungs to initiate tissue repair.
• Procedure:
o A second bronchoscopy is performed to transplant the cultured cells into the lungs. The cells are suspended in a sterile solution and delivered directly into the airways and alveoli.
o The dosage ranges from 0.7 × 10^6 to 5.2 × 10^6 cells per kilogram of body weight, tailored to the patient’s size and condition (PubMed).
o The procedure is performed under similar conditions as the initial bronchoscopy, with local anesthesia or sedation.
• Details: The cells are expected to integrate into the damaged lung tissue, regenerating the epithelial lining of the airways and alveoli. This process aims to improve gas exchange and lung function (Inside Precision Medicine).
• Safety: The transplantation is well-tolerated, with no significant side effects reported in trials, though minor bronchoscopy-related adverse events (e.g., sore throat) may occur.

5. Follow-up Period
• Purpose: Monitor patients for safety and efficacy over an extended period.
• Procedure:
o Patients are followed for 24 weeks (6 months) post-transplantation, with regular check-ups to assess lung function, exercise capacity, quality of life, and adverse events.
o Key metrics include:
 DLCO: Measures gas exchange efficiency. In trials, treated patients’ median DLCO increased from 30% to 39.7% at 12 weeks and 40.3% at 24 weeks (Hospital Healthcare Europe).
 Six-Minute Walk Distance (6MWD): Assesses exercise capacity. Treated patients showed a median increase from 410 meters to 447 meters at 24 weeks.
 St. George’s Respiratory Questionnaire (SGRQ): Evaluates quality of life. Scores decreased from 51.3% to 44.2%, indicating improvement.
 Imaging: CT scans monitor structural changes. Two patients with mild emphysema showed resolution of lesions at 24 weeks.

Safety is assessed by tracking adverse events, graded on severity (1 to 5, with 3 to 5 being serious). No grade 3 to 5 adverse events or serious adverse events were reported (PubMed).
• Details: The follow-up period is critical to determine the therapy’s long-term safety and efficacy. Transcriptomic analysis showed that higher P63 expression correlated with better outcomes, guiding future refinements.